Terms: = Bone cancer AND MAP2K4, MEK4, 6416, P45985, ENSG00000065559, SERK1, JNKK1, MKK4, PRKMK4, MAPKK4, JNKK, SEK1 AND Treatment
3 results:
1. Mutational Profile of Metastatic Breast cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract] [Full Text] [Related]
2. MicroRNA-27a promotes proliferation, migration and invasion by targeting map2k4 in human osteosarcoma cells.
Pan W; Wang H; Jianwei R; Ye Z
Cell Physiol Biochem; 2014; 33(2):402-12. PubMed ID: 24556602
[TBL] [Abstract] [Full Text] [Related]
3. MAPK7 and map2k4 as prognostic markers in osteosarcoma.
Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Filho RJ; Juliano Y; Toledo SR
Hum Pathol; 2012 Jul; 43(7):994-1002. PubMed ID: 22154052
[TBL] [Abstract] [Full Text] [Related]
